BCM
AQST icon

Bridgeway Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Bridgeway Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,900
Closed -$419K – 1233
2025
Q4 		$419K Sell
64,900
-2,800
-4% -$17.4K 0.01% 858
2025
Q3 		$378K Sell
67,700
-50,000
-42% -$216K 0.01% 858
2025
Q2 		$390K Sell
117,700
-50,000
-30% -$143K 0.01% 816
2025
Q1 		$486K Buy
+167,700
New +$508K 0.01% 749
2024
Q4 		– Sell
-192,856
Closed -$960K – 1202
2024
Q3 		$960K Hold
192,856
– – 0.02% 700
2024
Q2 		$501K Hold
192,856
– – 0.01% 858
2024
Q1 		$822K Hold
192,856
– – 0.02% 792
2023
Q4 		$390K Buy
192,856
+45,000
+30% +$79.5K 0.01% 1002
2023
Q3 		$226K Hold
147,856
– – 0.01% 1074
2023
Q2 		$244K Buy
147,856
+4,900
+3% +$8.86K 0.01% 1090
2023
Q1 		$163K Hold
142,956
– – ﹤0.01% 1137
2022
Q4 		$129K Hold
142,956
– – ﹤0.01% 1181
2022
Q3 		$167K Sell
142,956
-61,400
-30% -$69.4K ﹤0.01% 1170
2022
Q2 		$131K Sell
204,356
-64,200
-24% -$85.4K ﹤0.01% 1175
2022
Q1 		$701K Buy
268,556
+85,556
+47% +$250K 0.01% 859
2021
Q4 		$712K Hold
183,000
– – 0.01% 876
2021
Q3 		$798K Buy
183,000
+56,000
+44% +$220K 0.02% 888
2021
Q2 		$504K Sell
127,000
-25,000
-16% -$99.8K 0.01% 1061
2021
Q1 		$790K Hold
152,000
– – 0.01% 947
2020
Q4 		$813K Buy
152,000
+33,100
+28% +$198K 0.02% 791
2020
Q3 		$577K Buy
118,900
+38,400
+48% +$251K 0.01% 835
2020
Q2 		$391K Hold
80,500
– – 0.01% 943
2020
Q1 		$176K Buy
80,500
+5,500
+7% +$20.9K ﹤0.01% 1092
2019
Q4 		$437K Buy
75,000
+15,000
+25% +$78K 0.01% 1036
2019
Q3 		$191K Hold
60,000
– – ﹤0.01% 1189
2019
Q2 		$252K Sell
60,000
-37,000
-38% -$189K ﹤0.01% 1136
2019
Q1 		$670K Buy
+97,000
New +$680K 0.01% 910

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bridgeway Capital Management's AQST Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 64,900 shares — an estimated $419K sold.

Bridgeway Capital Management first reported a position in AQST in Q1 2019 and held it in 27 quarters. The position peaked at $960K in Q3 2024. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 64,900 Aquestive Therapeutics shares in Q1 2026, an estimated $419K.
  • Bridgeway Capital Management first reported a position in Aquestive Therapeutics in Q1 2019 and held it in 27 quarters.
  • Bridgeway Capital Management's Aquestive Therapeutics position peaked at $960K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.